RHJA
AMPH icon

Rice Hall James & Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

Rice Hall James & Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-187,348
Closed -$3.67M – 242
2026
Q1 		$3.67M Buy
187,348
+66,172
+55% +$1.62M 0.2% 109
2025
Q4 		$3.25M Sell
121,176
-8,163
-6% -$210K 0.18% 122
2025
Q3 		$3.45M Buy
+129,339
New +$3.34M 0.19% 116

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Rice Hall James & Associates's AMPH Position: Q2 2026 in Review

Rice Hall James & Associates sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 187,348 shares — an estimated $3.67M sold.

Rice Hall James & Associates first reported a position in AMPH in Q3 2025 and held it in 3 quarters. The position peaked at $3.67M in Q1 2026. 211 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Rice Hall James & Associates reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rice Hall James & Associates sold 187,348 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $3.67M.
  • Rice Hall James & Associates first reported a position in Amphastar Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Rice Hall James & Associates's Amphastar Pharmaceuticals position peaked at $3.67M in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.